Pharmaceutical balance sheets reflect a structural realignment of clinical research spending toward metabolic health and anti-obesity therapeutics. Capital expenditure in GLP-1 asset acquisition grew 34 percent year-over-year.
Clinical Trial Pipeline Adjustments
Contract research organizations report increased demand for long-term cardiovascular outcome trials focused specifically on metabolic interventions. The pivot is expected to consolidate mid-cap biotech valuations in the sector over the next 18 months.